Medically reviewed by Archana Sharma, DO Multiple myeloma is a chronic (long-term) blood cancer that affects plasma cells made in the bone marrow, which is spongy tissue found inside bones. While ...
Clinical Trials Arena on MSN
BMS to speak with regulators on mid-stage multiple myeloma success
An FDA AdCom voted for a new intermediate endpoint of MRD for accelerated approvals in multiple myeloma in 2024.
Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...
Iberdomide, which is being positioned as a successor to Revlimid, will continue in EXCALIBER-RRMM as the study progresses to ...
The EXCALIBER-RRMM study evaluated the efficacy and safety of iberdomide, an investigational cereblon E3 ligase modulator, in combination with dexamethasone and daratumumab in adults with RRMM.
During a live event, Adriana Rossi, MD, discussed easing CAR T-cell therapy access and highlighted cilta-cel's efficacy in earlier-line myeloma.
Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ambitions with a glimmer of hope. Following last week’s negative feedback ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Exicure, Inc. (XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient ...
SAN DIEGO, July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European ...
R - Renal (kidney) problems: Poor kidney function is a classic sign of multiple myeloma. The disease can trigger high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback